Gilead paid $1.275B for HCXT-2001, a phase 1 IL-23 inhibitor with no clinical data, targeting inflammatory diseases.
While Prime Video may not be thought of in the same realm as Apple TV when it comes to original sci-fi programming, the ...
Revival Gold Inc. reported earnings results for the full year ended June 30, 2026. For the full year, the company reported net loss was CAD 28.1 million compared to CAD 8.04 million a year ago. Basic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results